title: PPAR-γ activation limits angiotensin II-mediated atrial remodeling: one drug fits all AF patients?
authors: Institute of Medical Biochemistry and Molecular Biology, University Medicine Greifswald, Sauerbruchstrasse, D-17475 Greifswald, Germany. Electronic address: uwe.lendeckel@uni-greifswald.de.
authors: U
authors: U
authors: Lendeckel
authors: Institute of Medical Biochemistry and Molecular Biology, University Medicine Greifswald, Sauerbruchstrasse, D-17475 Greifswald, Germany.
authors: Carmen
authors: C
authors: Wolke
authors: Department of Cardiology and Intensive Care Medicine, St. Vincenz-Hospital Paderborn, Paderborn, Germany.
authors: Andreas
authors: A
authors: Goette
mesh_terms: D000804:Angiotensin II / Q000009:adverse effects*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000139:chemically induced / Q000517:prevention & control*; D064752:Atrial Remodeling / Q000187:drug effects; D006801:Humans; D047495:PPAR gamma / Q000819:agonists* / Q000235:genetics / Q000378:metabolism; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D047495:PPAR gamma; D044140:Receptor, Angiotensin, Type 1; D045162:Thiazolidinediones; D000804:Angiotensin II